Publisher
Springer Science and Business Media LLC
Reference15 articles.
1. Vyse S, Huang PH. Targeting EGFR exon 20 insertion mutations in non-small cell lung cancer. Signal Transduct Target Ther. 2019;4:5.
2. Gonzalvez F, Vincent S, Baker TE, et al. Mobocertinib (TAK-788): a targeted inhibitor of EGFR exon 20 insertion mutants in non-small cell lung cancer. Cancer Discov. 2021;11(7):1672–87.
3. US Food & Drug Administration. FDA grants accelerated approval to mobocertinib for metastatic non-small cell lung cancer with EGFR exon 20 insertion mutations [media release]. 15 Sep 2021.
4. Takeda Pharmaceuticals. EXKIVITY™ (mobocertinib) capsules, for oral use. 2021. https://www.accessdata.fda.gov. Accessed 17 Sep 2021.
5. Ariad Pharmaceuticals. ARIAD announces FDA clearance to begin clinical development of AP32788 [media release]. 1 Feb 2016.
Cited by
41 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献